The Boutique Investment Bank That Always Puts You First

We are a full-service, boutique investment bank providing corporate finance, M&A advisory, equity research, institutional sales, and market making and trading services.

The Boutique Investment Bank That Always Puts You First

We are a full-service investment bank providing corporate finance, M&A advisory, equity research, market making and institutional sales and trading services.

$ 0 B+

We Have Led Or Participated In Over $2.5 Billion in Transactions

Funding public companies is what we do.

We’ve invested our own capital over the years, and have relationships with institutional and strategic investors seeking quality opportunities.

Our Purpose

Your Goals Are Our Goals

Whether you’re seeking additional capital, looking to grow through acquisition, or considering the sale of your company, we can add value from our experience managing businesses and the expertise we’ve gained advising hundreds of clients.

Featured Clients

ClientLogos 300x150 02
ClientLogos 300x150 01
ClientLogos 300x150 03
ClientLogos 300x150 08
ClientLogos 300x150 08
Outlook Therapeutics
ClientLogos 300x150 08
Ascendiant Client Logos 11
Ascendiant Client Logos 12
Nemaura
Pro Dex
Endra Life Science
ClientLogos 300x150 01

Our Latest Financing Transactions

$3,300,000

Private Placement

Sole Placement Agent

February

2024

Endra Life Science

$6,200,000

At-the-Market Offering

Sole Sales Agent

February

2024

Sintx Technology

$4,000,000

Public Offering

Financial Advisor

February

2024

Verb Logo

$3,000,000

Private Placement

Sole Placement Agent

January

2024

Verb Logo

$960,000

At-the-Market Offering

Sole Sales Agent

December

2023

AIRTINC

$6,450,000

At-the-Market Offering

Sole Sales Agent

October

2023

$10,000,000

Public Offering

Financial Advisor

October

2023

$30,000,000

At-the-Market Offering

Sole Sales Agent

September

2023

$9,800,000

At-the-Market Offering

Sole Sales Agent

September

2023

$50,000,000

At-the-Market Offering

Sole Sales Agent

September

2023

$10,000,000

At-the-Market Offering

Sole Sales Agent

August

2023

Image001 2

$50,000,000

At-the-Market Offering

Sole Sales Agent

August

2023

Endra Life Science

$3,800,000

At-the-Market Offering

Sole Sales Agent

August

2023

$20,000,000

At-The-Market Offering

Sole Sales Agent

July

2023

$10,000,000

At-The-Market Offering

Sole Sales Agent

June

2023

Sintx Technology

$12,040,000

Public Offering

Financial Advisor

February

2023

Phunwaree

$5,000,000

Stock Repurchase Plan

Sole Agent

January

2023

Our Latest M&A Transactions

Royaldental Logo

has been acquired by Brident Dental & Orthodontics

Sole M&A Advisor

September
2022
Ascendiant Client Logos 12

acquired Technology Assessment & Transfer

Sole M&A Advisor

July
2022
Pinnacleprecisionsheetmedal Logo

has been acquired by The Partner Companies

Sole M&A Advisor

June
2022
South East

has been acquired by Pac-Dent, Inc.

Sole M&A Advisor

November
2021
ClientLogos 300x150 08

has been acquired by Vista Apex Dental

Sole M&A Advisor

October
2021
Ascendiant Client Logos 10

has acquired CapNostics, LLC

Sole M&A Advisor

October
2021
Ascendiant Client Logos 11

has been acquired by Gladstone Inv Corp

Sole M&A Advisor

August
2021
Gold Tech Industries

has been acquired by Graycliff Partners LP

Sole M&A Advisor

July
2021
Ascendiant Client Logos 12

acquired the assets of B4C, LLC

Sole M&A Advisor

July
2021
Vista Dental

has been acquired by Inverness Graham

Sole M&A Advisor

June
2018
Triex Tower

has been acquired by CED

Sole M&A Advisor

April
2018
Safe Flo (1)

has been acquired by Crosstex International

Sole M&A Advisor

December
2017
Riverside

has been acquired by Champlain Financial

Sole M&A Advisor

July
2017
Who We Are

What makes us the "go-to" investment bank

We’ve started, managed, and sold businesses of our own. Most investors and bankers have only worked on transactions, they’ve never run a business. Let us share our knowledge and insights to help you and your company

Our Values

01/08

Relationships

We’re in the money business, but we’re really in the people business. Investing in long-term relationships with clients is a fundamental principle of our business strategy, and one of the most rewarding and enjoyable aspects of what we do.

Our Values

02/08

Trust

Trust, along with excellent communication, is essential in any relationship. We value honesty, integrity, transparency, and reliability, and pledge to always do our best to earn your trust.

Our Values

03/08

Highest Standards

We’re not here to sell you, we’re here to serve you. That means doing what is best for your company and your shareholders – based on your needs and objectives, not ours. We’ve run businesses, too, and now we run an investment bank – that will always put you first.

Our Values

04/08

Serve Clients

Our goal is not to be the biggest bank, it’s to be the best – for the clients we serve. Your best financial partner, your best advisor, your best strategist, your best resource, your best sounding board. The best an investment bank has to offer.

Our Values

05/08

Success

Here’s our simple business philosophy and formula for success – maximize relationships, not fees. Success for us is a client achieving its goals and realizing its potential. When our capital is structured in a way that truly meets your needs – and allows you to hire more employees, open a new building, expand R&D, sell more product, or secure a strategic acquisition, that’s our measure of success.

Our Values

06/08

Experience

Most investors and bankers you meet have never run a business, and even fewer have managed a public company. We have unique perspective and insight from your side of the desk because we’ve been there. We appreciate what you do – tackling challenges and pursuing opportunities – and want to do our best to support you. Let our experience and expertise help you make the best decisions for your company.

Our Values

07/08

Freedom

A public company needs support from a lot of sources to achieve success. That means multiple investors, analysts, shareholders, and yes, investment banks. In short, you need a lot of investment bank friends, not just one. When an investment bank requires exclusivity or a right of first refusal following a capital raise, they are leveraging the relationship and limiting your company’s options. When you work with us, you have freedom, and that’s best for your business.

Our Values

08/08

Respect

Some investment banks are run like a money printing machine – deal after deal, and fees on top of fees. You get calls, e-mails, and texts all hours of the day, night, and weekends, pushing you to accept an offer. That’s not our style, and we’re respectful of your time and your life away from the office. We’ll listen to your needs and objectives, present ideas and solutions, and let you make the call.
Our Testimonials

Supporting companies and ideas for 22+ years

The first Ascendiant entity, Ascendiant Capital Group, was launched in 2001.

Prior to forming Ascendiant, the founding partners were involved with starting, investing in, and operating other businesses.  One of the companies was Odyssey Sports which was successfully sold to Callaway Golf.  Another company they started together was taken public, which provided direct experience raising capital, pursuing growth through acquisitions, and managing all aspects of a publicly-traded entity.

“We’ve had a great experience working with Ascendiant. Their team is very responsive and their At-the-Market instruments are extremely flexible and cost-effective. We definitely will be working with Ascendiant going forward on additional transactions in our portfolio of public companies.”

Jay Puchir

Chief Financial Officer

BitNile Metaverse, Inc. (Nasdaq: BNMV)

David Oddo
“I found Ascendiant to be a trusted partner in the sale of our business. During a pandemic-dominated economy, timing and presentation were critical elements of the sale process. Ascendiant’s diligence, counsel, and advice led to the successful closing of our transaction, and I am most appreciative to have worked with the Ascendiant team.”

David Oddo

President

Pinnacle Precision Sheet Metal Corporation

Robert Liscouski Ascendianttestimonial
“Ascendiant has distinguished themselves as a trusted partner with a clear focus on learning about our business and understanding our unique position in the marketplace. They were the first to discover our company at an early pre-revenue stage and have been of great help in guiding us through a variety of capital strategies – deal and non-deal related. We value our relationship with the Ascendiant team.”

Robert Liscouski

Chairman, President, & CEO

Quantum Computing Inc. (Nasdaq: QUBT)

South East Logo 2
“Over the last four decades, I have been engaged in the acquisition and divestiture of a variety of small, closely held pharmaceutical and medical device companies. Based on that experience, I highly recommend the Ascendiant team for their insight, professionalism, and perseverance in identifying appropriate entities on both sides of buy-sell transactions as well as for their record of success in facilitating completed deals.”

John Gruen

President

South East Instruments, LLC

Pavmed Dr Lishan
“Ascendiant has been a trusted advisor to our companies for several years and I deeply appreciate the team’s intense focus on building a long-term relationship and understanding a company’s needs. I believe this company-centric approach is a direct result of the fact that Ascendiant’s bankers have started and managed businesses of their own. They possess a unique understanding of the challenges faced in building a team, investing in R&D, and commercializing products and technologies. I look forward to a long and fruitful partnership with Ascendiant as we seek to build successful growth companies.”

Lishan Aklog, MD

Chairman & Chief Executive Officer, Co-Founder

PAVmed Inc (Nasdaq: PAVM) & Lucid Diagnostics Inc (Nasdaq: LUCD)

O'brien
“SINTX Technologies has had a constructive M&A engagement with Ascendiant for several years. Throughout the engagement, Ascendiant has listened to our evolving needs and conducted an organized, structured, and methodical approach to search for suitable targets. When potential targets were identified, Ascendiant professionally managed our discussions with the targets and provided valuable guidance to SINTX throughout the negotiations. The result has been two successful acquisitions in two years for SINTX.”

Dave O'Brien

Chief Operating Officer

SINTX Technologies, Inc. (Nasdaq: SINT)

Ascendiant Michael Feldschuh
“Ascendiant is very client-focused, and they are particularly astute at understanding the obstacles and pressures a micro-cap public company and management team faces. Our corporate structure is complex and somewhat unusual, and Ascendiant’s research analysts are adept at providing an in-depth investor report and analysis. We’re very appreciative of our relationship with Ascendiant, and the support they provide.”

Michael Feldschuh

CEO & President

Daxor Corporation (Nasdaq: DXR)

AIRTINC
“Ascendiant has provided our Company with the support and trading execution we’ve needed, and they continue to serve as an important resource. I’m able to talk with Ascendiant’s leadership directly, and they’re incredibly responsive and organized when it comes to execution. We’re very happy with our relationship with the Ascendiant team.”

Dan Philp

Senior Vice President of Corporate Development

Air T, Inc. (Nasdaq: AIRT)

Ascendiant Lawrencekenyon
“For where our Company was at the time, with our unique needs, I don’t think there was anyone better for us than Ascendiant. They listened and understood what the parameters were when it came to our Company’s needs. Instead of trying to fit us into a financing transaction that made sense for them, Ascendiant helped build a transaction that made sense for us.”

Lawrence Kenyon

CFO and Director

Outlook Therapeutics, Inc. (Nasdaq: OTLK)

Ascendiant Francois Michelon
Ascendiant has been a trusted partner for several years, advising us on market trends, introducing us to investors, and helping us raise capital at very efficient rates.  Ascendiant provides an incredible amount of personalized access and value-added support—they know our business and the markets.  We trust them, and they never try to upsell us—they invest in client relationships, rather than chasing transactions!”

Francois Michelon

Chairman & Chief Executive Officer

ENDRA Life Sciences, Inc. (Nasdaq: NDRA)

Ascendiant Jeffervin
“Ascendiant helped guide alternative forms of financing that didn’t jeopardize shareholder value. They provided our company with honest, fair assessments of our options and truly represented us as a client, rather than just another transaction. Ascendiant’s equity research provides prospective shareholders valuable insight into our company.”

Jeff Ervin

Chief Executive Officer

IMAC Holdings, Inc. (Nasdaq: IMAC)

Ascendiant Dr.sonnybal
Ascendiant is a boutique firm, not an industrial complex, and it shows. Their bankers are personable, and they listen, understand, and exercise persistence to achieve their client’s needs. I could not recommend them strongly enough.”

Dr. Sonny Bal

Chief Executive Officer

SINTX Technologies, Inc. (Nasdaq: SINT)

Tony Scott Headshot 122021
“Our company needed capital financing. A number of firms contacted us, and when we talked to the folks at Ascendiant, it became clear that they were suited to the type of situation that we were in.We discovered a great working relationship with Ascendiant, and they impressed us with their flexibility and responsiveness. There wasn’t a day that went by where we didn’t feel well-served by the Ascendiant team.”

Tony Scott

Chief Executive Officer

Intrusion, Inc. (Nasdaq: INTZ)

Alisha
“Ascendiant gave us several options for raising capital, and helped structure an ideal solution for our Company. Ascendiant has exceeded our expectations, and we are thrilled about the relationship we have with their team.”

Alisha Charlton

Chief Financial Officer

Pro-Dex, Inc. (Nasdaq: PDEX)

1516233594868
“Working closely with Ascendiant’s senior bankers has been a true pleasure, and has made the transaction process smoother and faster than I could have ever imagined.”

Nick Skrepetos

Chief Executive Officer

Bullseye Camera Systems

Riverside
“The Ascendiant team did an exceptional job guiding my fellow shareholders and me through a very complicated process. We will look forward to working with Ascendiant’s senior bankers on future projects.”

Russel Jacob

President

Riverside Lobster

Cosmetic Technologiess
“Ascendiant did an exceptional job guiding me through the unfamiliar landscape of selling my business and I’m excited about the future!”

Ron Lewis

Chief Executive Officer

Cosmetic Technologies

Safe Flo (1)
“Having Ascendiant as our Investment Bank was crucial to getting our sale completed. We appreciated their knowledge of the buyers, and their ability to help us navigate the intricacies of this type of a transaction.”

Rich Bushman

Chief Executive Officer

Safe-Flo Dental Products

Ascendiant Billcritchfield
“Ascendiant demonstrated considerable persistence, determination, and flexibility in successfully completing our institutional financing. Ascendiant had the foresight to see the positive and compelling aspects of our story, successfully communicate that story to others in the financial community, and bring the financing across the finish line.”

Bill Critchfield

Chief Financial Officer

Corgenix Medical Corporation

Ascendiant Thomas Sandgaard
“Ascendiant supplied our Company with capital at a very important time in our development, and the Ascendiant team has been a trusted and valuable advisor. Ascendiant’s timely capital and relationships with other institutional investors has contributed to our Company’s profitability and improvement in stock price and trading volume. Ascendiant approaches their business with professionalism, integrity, and follow-through. I believe the Ascendiant group is as knowledgeable and experienced as any other in the funding of high growth companies and in providing guidance and support.”

Thomas Sandgaard

Chairman, President, & CEO

Zynex, Inc. (Nasdaq: ZYXI)

Client Testimonial

“Ascendiant has been a trusted advisor to our companies for several years and I deeply appreciate the team’s intense focus on building a long-term relationship and understanding a company’s needs. I believe this company-centric approach is a direct result of the fact that Ascendiant’s bankers have started and managed businesses of their own. They possess a unique understanding of the challenges faced in building a team, investing in R&D, and commercializing products and technologies. I look forward to a long and fruitful partnership with Ascendiant as we seek to build successful growth companies.”
Pavmed Dr Lishan

Lishan Aklog, MD

Chairman & Chief Executive Officer, Co-Founder

PAVmed Inc (Nasdaq: PAVM) & Lucid Diagnostics Inc (Nasdaq: LUCD)

Ascendiant By The Numbers

$ 0 B+
In Financing Transactions
0 +
M&A Transactions
0 +
Covered Companies
0 +
Years In Business
What We Do

Value-Added Services Backed by Experience and Dedication

With Ascendiant, you’re not another name on a spreadsheet.  You’re a client we care about now and well into the future. We’ll listen to your needs and objectives, and do our best to apply our skills, experience, and expertise to your situation.

Corporate Finance

We provide equity capital, debt financing, and related strategic guidance and advisory services to public and private companies, while generating investment opportunities for institutional, accredited, and strategic investors.  Ascendiant’s Investment Banking division also assists private companies interested in going public.

Mergers & Acquisitions

Ascendiant Capital Markets, LLC provides advisory services for Mergers & Acquisitions in both a sell-side and buy-side capacity. The members of Ascendiant’s Investment Banking division average over twenty-five years of experience, and have successfully initiated, negotiated, and completed over 300 M&A transactions across a wide range of industry sectors.    

Equity Research

Ascendiant’s Equity Research team provides independent research, analysis, and reporting to the investment community for sectors such as: healthcare (biotech, life sciences, medical device), technology, energy, consumer, media and entertainment, and the internet.

Institutional Sales

Ascendiant’s Institutional Sales division supports the efforts of Ascendiant’s Equity Research division, generating investment ideas and high-value market research for the firm’s institutional clients and investment managers.

Market Making & Trading

Ascendiant’s Market Making & Trading division utilizes the firm’s capital to provide liquidity, while making markets in a significant number of equity securities.  Our traders average over fifteen years’ experience, and provide reliable and efficient order execution.

Access Our Research Reports

Our Research Reports are an easy way to digest the trends and changes of our clients. We are fortunate to work with such amazing companies and continue to provide you with regular report updates.

Interested in learning more about our Research Reports? Click the link below to access our latest reports on the clients we work with.

WISA Q2 2023

Nasdaq: WISA

Ascendiant Research Report

AIM Q4 2021

NYSE American: AIM

Ascendiant Research Report

AIM Q1 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q2 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q3 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q4 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q1 2023

NYSE American: AIM

Ascendiant Research Report

ALZN Q3 FY22

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q1 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q2 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q3 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q4 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q1 FY24

Nasdaq: ALZN

Ascendiant Research Report

Access Our Research Reports

WISA Q2 2023

Nasdaq: WISA

Ascendiant Research Report

AIM Q4 2021

NYSE American: AIM

Ascendiant Research Report

AIM Q1 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q2 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q3 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q4 2022

NYSE American: AIM

Ascendiant Research Report

AIM Q1 2023

NYSE American: AIM

Ascendiant Research Report

ALZN Q3 FY22

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q1 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q2 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q3 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q4 FY23

Nasdaq: ALZN

Ascendiant Research Report

ALZN Q1 FY24

Nasdaq: ALZN

Ascendiant Research Report

Ascendiant News

February 26, 2024
Ascendiant Initiates Equity Research Coverage on LiqTech International, Inc. (Nasdaq: LIQT)
February 22, 2024
Ascendiant Capital Markets LLC Serves as Sole Placement Agent on $3,300,000 Private Placement for AIM ImmunoTech Inc. (NYSE American: AIM)
February 15, 2024
Ascendiant Capital Markets LLC Serves as Sole Sales Agent on $6,200,000 At-the-Market (ATM) Offering for ENDRA Life Sciences Inc. (Nasdaq: NDRA)
February 12, 2024
Ascendiant Initiates Equity Research Coverage on IGC Pharma, Inc. (NYSE American: IGC)
February 5, 2024
Ascendiant Capital Markets LLC Serves as Financial Advisor on $4,000,000 Public Offering for SINTX Technologies, Inc. (Nasdaq: SINT)
January 5, 2024
Ascendiant Capital Markets LLC Serves as Sole Placement Agent on $3,000,000 Private Placement for Verb Technology Company, Inc. (Nasdaq: VERB)
December 18, 2023
Ascendiant Capital Markets LLC Serves as Sole Sales Agent on $960,000 At-the-Market (ATM) Offering for Verb Technology Company, Inc. (Nasdaq: VERB)
November 13, 2023
Ascendiant Initiates Research Coverage on The Singing Machine Company, Inc. (Nasdaq: MICS)
October 30, 2023
Ascendiant Initiates Research Coverage on Vision Marine Technologies Inc. (Nasdaq: VMAR)
October 19, 2023
Ascendiant Capital Markets LLC Serves as Sole Sales Agent on $6,450,000 At-the-Market (ATM) Offering for Air T, Inc. (Nasdaq: AIRT) and Air T Funding (Nasdaq: AIRTP)
October 5, 2023
Ascendiant Capital Markets LLC Serves as Financial Advisor on $10,000,000 Public Offering for Genasys Inc. (Nasdaq: GNSS)
October 2, 2023
Ascendiant Initiates Equity Research Coverage on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)